Literature DB >> 8665591

Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.

D I Gabrilovich1, S Nadaf, J Corak, J A Berzofsky, D P Carbone.   

Abstract

Antitumor CTL responses were studied in a model tumor hearing a mutant human p53 gene. We found ineffective induction of antitumor CTL in mice bearing these tumors associated with measurable defects in the function of dendritic cells (DC) from these animals. In this study we investigate the mechanism of this defect in mature DC and find that functional DC can be generated by growth from the bone marrow of tumor-hearing animals. Tumor cell supernatants did not affect the function of mature DC obtained from the spleen of tumor-bearing animals, but significantly suppressed the ability to generate functional DC from the bone marrow of control mice in vitro. This suggests that tumor cells may release factors which block early stages of DC maturation from precursors. DC generated from the bone marrow of tumor-bearing mice showed normal potential to stimulate allogeneic T cells, to stimulate anti-mutant p53 peptide-specific cytotoxic T cells, and to induce anti-p53 CTL responses in vivo in control mice. Repeated immunization with peptide-pulsed DC generated from the bone marrow of control mice (every 4-5 days) blocked progression of established tumors. Immunization of mice with peptide-pulsed DC obtained from the spleen of tumor-bearing mice (4 weeks after tumor injection) did not affect the tumor growth, whereas immunization with peptide-pulsed DC generated from bone marrow of tumor-bearing mice resulted in significantly prolonged survival and delayed tumor growth. Tumor progression was associated with change of the balance Th1/Th2 cells in favor of the Th2-like cytokine profile, while effective immunization was associated with a shift to the Th1 phenotype. Thus, frequent immunization of mice with mutant p53 peptide-pulsed DC generated from stem cells of tumor-bearing hosts can induce effective antitumor CTL responses associated with production of Th1 cells and lead to significant antitumor effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665591     DOI: 10.1006/cimm.1996.0140

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  34 in total

Review 1.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 2.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

4.  Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse.

Authors:  Akimitsu Takagi; Haruo Ikemura; Takeshi Matsuzaki; Mikiko Sato; Koji Nomoto; Masami Morotomi; Teruo Yokokura
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

5.  Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model.

Authors:  Carina Riediger; Gerhard Wingender; Percy Knolle; Sebastian Aulmann; Wolfgang Stremmel; Jens Encke
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-10       Impact factor: 4.553

Review 6.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

7.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.

Authors:  Bei Wang; Jin He; Chen Liu; Lung-Ji Chang
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

8.  Combined treatment of an intratumoral injection of dendritic cells and systemic chemotherapy (Paclitaxel) for murine fibrosarcoma.

Authors:  Gwang-Seong Choi; Moon-Hee Lee; Soon-Ki Kim; Chul-Soo Kim; Hong-Sik Lee; Moon-Whan Im; Hye-Yun Kil; Do-Hwan Seong; Jong-Rok Lee; Woo-Chul Kim; Min-Geol Lee; Sun U Song
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

Review 9.  Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

Authors:  Yolanda Nesbeth; Jose R Conejo-Garcia
Journal:  Clin Dev Immunol       Date:  2010-11-07

10.  Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Lauren T Southerland; Ying Lu; Kataryna A Darlak; Cynthia R Giver; Douglas W McMillin; Wayne A C Harris; David L Jaye; Edmund K Waller
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.